FYI: If you're a woman on birth control, Foundayo's label says more than the marketing does.

Eli Lilly's Foundayo, the newer of the two oral GLP-1 pills for weight loss, is having a measurably slow launch. We're going to walk through what the financial press is reporting, what they're missing, and what it means if you were considering Foundayo, especially if you're a woman currently on the pill.

Heads up before we go further: this issue is news-y and runs slightly long. It's worth it.

This is Off Label, Not Medical Advice.

Let's go.

The Morning Read: Lilly's Foundayo is having a slow launch. Wall Street is covering the wrong story. The patient-side reasons are buried in the package insert.

On April 1, 2026, the FDA approved Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 pill for weight loss. It is the second oral GLP-1 weight loss medication on the US market, after Novo Nordisk's oral Wegovy, which launched in January.

The approval was historic. Foundayo cleared the FDA in 50 days from filing, the fastest new molecular entity approval since 2002, granted via the FDA's new Commissioner's National Priority Voucher pilot program. Lilly began shipping through LillyDirect on April 6 and expanded to retail pharmacies and telehealth providers on April 9.

Then came the prescription numbers.

On Thursday April 24, Reuters reported IQVIA data showing Foundayo recorded 1,390 prescriptions in its first week (a two-day capture window) and 3,707 in its second week. For context, oral Wegovy logged 3,071 prescriptions in its first four days and 18,410 in its second full week. Foundayo is running at roughly 20% of oral Wegovy's launch pace.

Lilly stock fell 4% on Friday. Novo Nordisk's US-listed shares rose 6%. Wall Street called it a slow launch and pointed to first-mover advantage as the explanation.

Wall Street is partially right. They're also missing the bigger story.

This is the part the financial press isn't leading with.

Foundayo, like other GLP-1s, slows gastric emptying. That mechanism is part of how it works for weight loss (food sits in your stomach longer, you feel full sooner). It's also the reason the drug interferes with the absorption of other oral medications taken at the same time. Lilly's official prescribing information flags two specific interactions that affect a substantial share of the people considering Foundayo for weight loss.

Pulled directly from Lilly's prescribing information: patients using oral hormonal contraceptives are advised to switch to a non-oral contraceptive method (IUD, implant, injection, ring, patch) or add a barrier method (condoms, diaphragm) for 30 days after starting Foundayo and for 30 days after each dose escalation.

Foundayo has six dose levels: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. Each escalation requires at least 30 days at the prior dose. That means a woman titrating up to the highest dose faces approximately seven separate 30-day windows where her contraception protocol must be modified, including the initial start window.

For women who specifically wanted Foundayo because it's a pill (the marketing pitch is "take it any time of day, with or without food, no water restrictions"), the actual day-to-day reality is meaningfully more complicated than the marketing suggests.

If you take simvastatin (brand name Zocor), Lilly's prescribing information caps your simvastatin at 20 mg per day when combined with Foundayo. Standard maintenance simvastatin doses are typically 10, 20, or 40 mg per day. The 80 mg dose has been restricted since 2011 due to muscle injury risk. Roughly half of simvastatin users are on doses above the 20 mg cap.

Patients on the higher doses would need to switch to a different statin. The Foundayo label specifically notes that rosuvastatin (Crestor) and atorvastatin (Lipitor) do not have the same interaction. The fix is straightforward, but it's still a prescribing decision that has to happen before someone starts Foundayo.

If you're already managing type 2 diabetes with insulin or sulfonylureas, Foundayo can increase the risk of hypoglycemia (low blood sugar). Your doctor may need to lower the dose of those medications when you start Foundayo and monitor blood sugar more frequently in the early weeks. This affects fewer patients than the contraceptive interaction, but it's clinically significant when it applies.

None of these interactions is being hidden by Lilly. They are all in the official prescribing information, available on Lilly's website and on every pharmacy reference site. The issue is what the financial press is leading with versus what readers actually need to know.

Three context points the financial coverage isn't fully accounting for.

The Commissioner's National Priority Voucher (CNPV) pilot program, run by FDA Commissioner Martin Makary, is designed to compress drug review timelines through accelerated multidisciplinary review. Foundayo was the fifth CNPV approval and the first new molecular entity approved under the program. The 50-day approval landed 294 days before the standard PDUFA date of January 20, 2027.

Speed is the headline. The unstated cost is that drug companies receiving CNPV approval typically have less pre-launch preparation time than a normal rollout. Six to ten months of prescriber education, PBM negotiation, inventory build, and patient-support infrastructure get compressed into weeks. Some of what Wall Street is calling "slow demand" may actually be "Lilly hadn't finished prepping the launch when approval landed."

This is not an excuse. It is context. The financial analysts have flagged weeks 8 to 12 (mid-May through June) as the meaningful evaluation window precisely because the early weeks reflect operational readiness more than they reflect demand.

On April 2, 2026, the day after the FDA approved Foundayo, Novo Nordisk released cross-trial comparison data claiming oral Wegovy produced approximately 3 percentage points more weight loss than Foundayo and that Foundayo patients had roughly 14 times higher odds of stopping treatment due to gastrointestinal side effects.

The comparison was an indirect treatment comparison, not a head-to-head trial. Novo used its OASIS 4 trial of oral semaglutide and compared it to Lilly's ATTAIN-1 trial of orforglipron. Different trials, different populations, different protocols, methodologically adjusted but not directly comparable.

If the methodology debate sounds familiar, it should. Yesterday's issue walked you through how the same drug can produce wildly different results across cost-effectiveness studies because of the population, time horizon, and methodology choices each study makes. The exact same dynamic just played out in real time with Novo's release. Lilly's response was essentially "head-to-head trials are the gold standard, and there isn't one yet."

There is one head-to-head data point worth knowing. ACHIEVE-3, published in The Lancet on February 26, 2026, is the only head-to-head trial between Foundayo and oral semaglutide. It was in type 2 diabetes patients (not obesity), and Foundayo at 36 mg outperformed oral semaglutide at 14 mg by approximately 3 percentage points on weight reduction. Same drugs. Different trial populations. Opposite result from Novo's cross-trial comparison.

Both companies are using different data to support opposite narratives. The first thing to notice is that this is exactly what Issue #12 trained you to spot.

Cash price through LillyDirect: $149 per month for the 0.8 mg starter dose, scaling to $299 per month at the higher doses. For comparison, Lilly's own injectable Zepbound has historically cash-priced at $499 per month and higher.

For uninsured or underinsured patients, Foundayo is genuinely opening GLP-1 access to a population that couldn't afford injectables. With insurance, copays could be as low as $25 per month with a Lilly savings card. Even with the slow launch, Foundayo materially expands GLP-1 affordability. That's the win Wall Street isn't leading with.

Text your doctor this: "I've been reading about Foundayo, the new oral GLP-1 from Lilly. The package insert flags interactions with oral birth control and simvastatin that I want to think through before we make a decision. Specifically, I'm currently on (insert your current oral medications, including birth control or any cholesterol medication). Can we discuss whether Foundayo is the right fit given those medications, or whether oral Wegovy or an injectable would be a better choice for my situation?"

Copy, paste, send.

The financial press treats this as a stock story. Off Label treats it as a patient story. Reuters, CNBC, and Bloomberg are covering Lilly versus Novo as a market-share fight. The questions Off Label is asking are different. What does this mean for the woman on the pill trying to pick a GLP-1? What does this mean for the older adult on simvastatin who finally has an affordable option? What does this mean for the uninsured patient who heard about a $149 pill but doesn't know about the drug interactions?

Different lens. Different audience. Different value.

The CNPV program is going to create more "fast approval, slow launch" stories. Foundayo is the first new molecular entity approved under the program. Future approvals will follow the same template: compressed timelines, less pre-launch prep, faster patient access but potentially less comprehensive prescriber education at launch. This is the price of speed. There are real benefits for patients with serious conditions who would otherwise wait years. There are also real costs in the form of launches that look chaotic from the outside and confusing from the inside. Off Label readers should know the pattern is going to repeat.

The "convenient pill" marketing has limits. Foundayo is being marketed as the GLP-1 you can take anytime, with or without food. That marketing is technically accurate. It also obscures the operational reality for women on oral contraceptives and adults on simvastatin. Marketing that emphasizes one form of convenience while burying another form of inconvenience is exactly the pattern Off Label exists to make visible.

There is a structural advantage worth flagging. Foundayo is a small molecule with a molecular weight of roughly 902 grams per mole, more like a statin than like other GLP-1s. Every other GLP-1 currently on the market is a peptide, including oral Wegovy. Peptides are large, fragile molecules that get destroyed in the stomach. They require specialized delivery systems and complex manufacturing. Small molecules like Foundayo are fundamentally easier to manufacture at scale, easier to formulate, and easier to dose flexibly. That manufacturing advantage matters for the medium-term price trajectory of GLP-1s, even if today's prescription numbers favor Novo.

Watch this: Lilly's Q1 2026 earnings call this Thursday April 30 at 10 AM ET. Management will field analyst questions on Foundayo's prescription trajectory, the Novo cross-trial comparison study, and the launch playbook for the next 60 days. Their commentary will reset the narrative or confirm the slow start. Then Novo's Q1 2026 earnings call on May 6 will provide the counterpoint. Then the Obesity Medicine Association annual meeting in early May will surface the comparative data presentations both companies are using to fight for share. Three news beats in nine days. We will be tracking all three.

Tomorrow we get back to the contrarian beat we had planned for today. An unexpected industry quietly fighting back hard against GLP-1s, with internal data they didn't want public.

Hit reply and tell us what you want us to cover. Every reply is read. Story tips: [email protected]

See you in your inbox.

— Off Label

This is Off Label, Not Medical Advice. Content is for informational purposes only. Always consult a qualified healthcare provider before making medical decisions about starting, stopping, or modifying any prescription medication. Off Label is not anti-Foundayo, not anti-Lilly, and not anti-Novo. Foundayo is FDA-approved, has demonstrated meaningful weight loss in clinical trials, and represents a real patient-access win for the substantial population that could not afford injectable GLP-1s. The thesis of this issue is that the patient-side details buried in the package insert deserve the same attention the financial press is giving to the prescription numbers. The drug interactions discussed in this issue are taken directly from Lilly's official prescribing information and are not in dispute. The cross-trial comparison data discussed in this issue comes from a Novo Nordisk press release; both companies are presenting their own data favorably, and head-to-head trial data on weight loss outcomes is not yet available. Patients considering Foundayo, oral Wegovy, or any other GLP-1 should review the prescribing information for their specific medication and discuss interactions with their healthcare provider.